ERBB2 and hepatoid adenocarcinoma: Based on the molecular characteristics of our reported case of hepatoid adenocarcinoma (Her-2 is negative, PD-L1 is strongly positive), the first-line combination of pembrolizumab and FP regimen chemotherapy progressed rapidly, while the second-line combination of parolizumab and CAPEOX regimen achieved good efficacy, achieving partial relief and significant clinical symptom relief, consistent with current clinical trial results.